All Drug Discovery articles – Page 31
-
ArticleWomen in STEM with Dr Catherine Sheehan
In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in ...
-
ArticleThe future of mRNA biology and AI convergence
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly ...
-
ReportBeyond the lab: cancer research
Our inaugural report is an exploration of the remarkable advancements in cancer research and the field of drug discovery.
-
ArticleWomen in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership, ...
-
NewsNew method to develop therapeutics for autoimmune diseases
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
-
ArticleExploring liver disease therapies
Ochre Bio is at the forefront of therapeutic innovation, focusing primarily on liver diseases. Their core mission revolves around the development of RNA therapies, primarily in the preclinical stage, using a 'human-first' approach. They employ real human tissue, such as 'liver slices' and whole human livers, in their preclinical pipeline ...
-
ArticleThe effectiveness of nanoparticles in chemotherapy
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
-
ArticleCombining autotaxin and TGF-β inhibitors in cancer
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and ...
-
NewsNano-sized traps enable better study of proteins
Researchers have developed a new method to study protein clumps that occur in many difficult-to-treat diseases.
-
Article
Natural killer cells: Looking good for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
-
ArticleBreaking down barriers across the DMTA cycle
In this article, David Bardsley, Commercial Director, and Nick Foster, Vice President of Discovery CRO at Cresset, explore the challenges that occur when approaching drug discovery in silos and how harnessing advances in technology can help to overcome them.
-
ArticleThe power of combinations in blood cancers
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers ...
-
ArticleCancer drug discovery: protein-ligand interactions
Dr Rob van Montfort, a leading researcher at the Centre for Cancer Drug Discovery (CCDD) within The Institute of Cancer Research, London, is at the forefront of cancer drug discovery. Focusing on protein-ligand interactions, his work utilises structural biology and biochemical methods to help the discovery of novel small-molecule drugs ...
-
NewsNew small molecule blocks immune response signalling pathway
A new small molecule has great promise for the treatment of autoimmune diseases by inhibiting the proinflammatory signalling pathway.
-
NewsKey epitope can trigger tumour cell death
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
-
ArticleEmotional scars: stigma with female adult acne
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany, has highlighted a previously underestimated aspect of acne's impact on individuals: its profound influence on social perception.
-
ArticleCould scratching nerve cells be the itch solution?
The sensation of itch is something everyone has experienced at some point in their lives. It's a natural response to various irritants, from insect bites to dry skin. But what happens when the urge to itch becomes relentless, causing discomfort and, in some cases, serious health problems?
-
ArticleThe inner workings of environmental bacterium
Researchers have achieved profound insights into the inner workings of a prevalent environmental bacterium.
-
ArticleSino Biological: new US centre for bioprocessing
Sino Biological are pleased to announce the formal opening of its new center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.
-
ArticleAntibody-drug conjugates payloads: then, now and next
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.